Blood · 2017 · 60 citations · 23 references
MedicineHematologyOncologyHematologic OncologyMolecular DiagnosticsMolecular OncologyCancer Molecular DiagnosticsCirculating Tumor CellsCirculating Tumor Dna AnalysisDna SequencingMyelodysplastic SyndromesTumor MarkersCirculating Tumor BiomarkersCirculating Tumor Cell MonitoringCirculating Tumor Dna DetectionCirculating Tumor Dna DynamicsCirculating Tumor Dna SequencingCirculating Tumor Dna TestingCirculating Tumor Markers
The diagnosis and monitoring of myelodysplastic syndromes (MDSs) are highly reliant on bone marrow morphology, which is associated with substantial interobserver variability. Although azacitidine is the mainstay of treatment in MDS, only half of all patients respond. Therefore, there is an urgent need for improved modalities for the diagnosis and monitoring of MDSs. The majority of MDS patients have either clonal somatic karyotypic abnormalities and/or gene mutations that aid in the diagnosis and can be used to monitor treatment response. Circulating cell-free DNA is primarily derived from hematopoietic cells, and we surmised that the malignant MDS genome would be a major contributor to cell-free DNA levels in MDS patients as a result of ineffective hematopoiesis. Through analysis of serial bone marrow and matched plasma samples (n = 75), we demonstrate that cell-free circulating tumor DNA (ctDNA) is directly comparable to bone marrow biopsy in representing the genomic heterogeneity of malignant clones in MDS. Remarkably, we demonstrate that serial monitoring of ctDNA allows concurrent tracking of both mutations and karyotypic abnormalities throughout therapy and is able to anticipate treatment failure. These data highlight the role of ctDNA as a minimally invasive molecular disease monitoring strategy in MDS.
23
International Scoring System for Evaluating Prognosis in Myelodysplastic Syndromes
Peter L. Greenberg, Christopher Cox, Michelle M. LeBeau et al. · Blood · 1997 · 4.5K citations · Full text
Revised International Prognostic Scoring System for Myelodysplastic Syndromes
Peter L. Greenberg, Heinz Tuechler, Julie Schanz et al. · Blood · 2012 · 3.1K citations · Full text
Pierre Fenaux, Ghulam J. Mufti, Eva Hellström‐Lindberg et al. · The Lancet Oncology · 2009 · 2.6K citations · Full text
Frequent pathway mutations of splicing machinery in myelodysplasia
Kenichi Yoshida, Masashi Sanada, Yuichi Shiraishi et al. · Nature · 2011 · 2.1K citations
Clinical and biological implications of driver mutations in myelodysplastic syndromes
Elli Papaemmanuil, Moritz Gerstung, Luca Malcovati et al. · Blood · 2013 · 1.8K citations